Latest Cadence Pharmaceuticals (CADX) Headlines
Post# of 4
Posted On: 03/12/2014 6:55:17 PM
Latest Cadence Pharmaceuticals (CADX) Headlines
Cadence Pharmaceuticals Shares Up 70.8% Since SmarTrend's Buy Recommendation (CADX)
Comtex SmarTrend(R) - Mon Mar 10, 9:09AM CDT
SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 15th, 2013 at $8.20. In approximately 4 months, Cadence Pharmaceuticals has returned 70.84% as of today's recent price of $14.00.
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Wider-Than-Expected Q4 Loss at Cadence Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 12:44PM CST
The company posted a net loss of 5 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of 3 cents. The loss reported in the year-ago quarter was 25 cents per share.
Cadence Pharmaceuticals Has Returned 70.7% Since SmarTrend Recommendation (CADX)
Comtex SmarTrend(R) - Fri Feb 28, 4:43PM CST
SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 15th, 2013 at $8.20. In approximately 4 months, Cadence Pharmaceuticals has returned 70.71% as of today's recent price of $13.99.
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Fri Feb 28, 3:00PM CST
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and twelve months ended December 31, 2013.
Patent Update from Mallinckrodt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 4:20PM CST
Mallinckrodt's Xartemis XR gains patent approval.
Cadence Pharmaceuticals Stock Sees Short Interest Decline 25.7%
MarketNewsVideo.com - Thu Feb 27, 2:05PM CST
The most recent short interest data has been released by the NASDAQ for the 02/14/2014 settlement date, which shows a 745,689 share decrease in total short interest for Cadence Pharmaceuticals Inc , to 2,154,610, a decrease of 25.71% since...
BNY Mellon U.S. Master Trust Universe Up 14.4% in 2013
PR Newswire - Wed Feb 26, 7:15AM CST
The median return of the BNY Mellon U.S. Master Trust Universe was +4.7% for the fourth quarter of 2013, resulting in year-to-date performance for the typical fund of +14.4%, ahead of the +12.6% returned in 2012. The average plan posted gains in three of four quarters last year.
Shares of CADX Up 71.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 21, 11:00AM CST
SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 15th, 2013 at $8.20. In approximately 3 months, Cadence Pharmaceuticals has returned 71.02% as of today's recent price of $14.02.
Lifshitz & Miller Law Firm Announces Investigation of Cadence Pharmaceuticals, Inc., Chindex International, Inc., LCA-Vision, Inc., North Valley Bancorp and Texas Industries, Inc.
PR Newswire - Wed Feb 19, 2:48PM CST
Cadence Pharmaceuticals, Inc.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc. in Connection With the Sale of the Company to Mallinckrodt plc
Business Wire - Mon Feb 17, 12:54PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc ("MNK").
This Week in Biotech: Three Strikes and You're Out!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 15, 1:10PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
CADENCE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Fri Feb 14, 2:50PM CST
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (NASDAQ GS: CADX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Mallinckrodt plc ("Mallinckrodt") (NYSE: MNK), in a transaction valued at approximately $1.3 billion.
SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc.
Business Wire - Fri Feb 14, 12:06PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc ("MNK").
Downgrade Alert for Cadence Pharmaceuticals (CADX)
Comtex SmarTrend(R) - Fri Feb 14, 6:58AM CST
Cadence Pharmaceuticals (NASDAQ:CADX) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $14.04 on volume of 4.3 million shares, above average daily volume of 3.5 million. In the past 52 weeks, Cadence Pharmaceuticals share prices have been bracketed by a low of $4.45 and a high of $14.04 and closed yesterday at $14.04, 216% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 2.5% while the 200-day MA has risen 1.2%.
INVESTOR ALERT: LEVI & KORSINSKY, LLP Announces Investigation of CADENCE PHARMACEUTICALS INC. and Its Board of Directors in Connection with the Sale of the Company to Mallinckrodt plc -- CADX
Business Wire - Thu Feb 13, 4:33PM CST
Levi & Korsinsky is investigating the Board of Directors of Cadence Pharmaceuticals Inc. ("Cadence" or "the Company") (NasdaqGS:CADX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Mallinckrodt plc.
CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP is Investigating Cadence Pharmaceuticals, Inc. (CADX) in Relation to the Proposed Sale of the Company to Mallinckrodt plc
Business Wire - Thu Feb 13, 2:24PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (NasdaqGS:CADX) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Mallinckrodt in a cash deal valued at approximately $1.3 billion. Under the terms of the proposed transaction, Cadence's stockholders will receive $14.00 for each share of Cadence common stock they own.
Everyone Wins in This Big Pharma Buyout
David Williamson, The Motley Fool - Motley Fool - Wed Feb 12, 7:30PM CST
Shares of Mallinckrodt were up 10% after the company announced that it's buying Cadence for $1.3 billion. Shares of Cadence performed even better, up about 25% on the buyout news. The catalyst for the acquisition is painkiller Ofirmev, which...
Cadence Pharmaceuticals Shares Up 70.8% Since SmarTrend's Buy Recommendation (CADX)
Comtex SmarTrend(R) - Mon Mar 10, 9:09AM CDT
SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 15th, 2013 at $8.20. In approximately 4 months, Cadence Pharmaceuticals has returned 70.84% as of today's recent price of $14.00.
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Wider-Than-Expected Q4 Loss at Cadence Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 12:44PM CST
The company posted a net loss of 5 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of 3 cents. The loss reported in the year-ago quarter was 25 cents per share.
Cadence Pharmaceuticals Has Returned 70.7% Since SmarTrend Recommendation (CADX)
Comtex SmarTrend(R) - Fri Feb 28, 4:43PM CST
SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 15th, 2013 at $8.20. In approximately 4 months, Cadence Pharmaceuticals has returned 70.71% as of today's recent price of $13.99.
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Fri Feb 28, 3:00PM CST
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and twelve months ended December 31, 2013.
Patent Update from Mallinckrodt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 4:20PM CST
Mallinckrodt's Xartemis XR gains patent approval.
Cadence Pharmaceuticals Stock Sees Short Interest Decline 25.7%
MarketNewsVideo.com - Thu Feb 27, 2:05PM CST
The most recent short interest data has been released by the NASDAQ for the 02/14/2014 settlement date, which shows a 745,689 share decrease in total short interest for Cadence Pharmaceuticals Inc , to 2,154,610, a decrease of 25.71% since...
BNY Mellon U.S. Master Trust Universe Up 14.4% in 2013
PR Newswire - Wed Feb 26, 7:15AM CST
The median return of the BNY Mellon U.S. Master Trust Universe was +4.7% for the fourth quarter of 2013, resulting in year-to-date performance for the typical fund of +14.4%, ahead of the +12.6% returned in 2012. The average plan posted gains in three of four quarters last year.
Shares of CADX Up 71.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 21, 11:00AM CST
SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 15th, 2013 at $8.20. In approximately 3 months, Cadence Pharmaceuticals has returned 71.02% as of today's recent price of $14.02.
Lifshitz & Miller Law Firm Announces Investigation of Cadence Pharmaceuticals, Inc., Chindex International, Inc., LCA-Vision, Inc., North Valley Bancorp and Texas Industries, Inc.
PR Newswire - Wed Feb 19, 2:48PM CST
Cadence Pharmaceuticals, Inc.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc. in Connection With the Sale of the Company to Mallinckrodt plc
Business Wire - Mon Feb 17, 12:54PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc ("MNK").
This Week in Biotech: Three Strikes and You're Out!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 15, 1:10PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
CADENCE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Fri Feb 14, 2:50PM CST
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (NASDAQ GS: CADX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Mallinckrodt plc ("Mallinckrodt") (NYSE: MNK), in a transaction valued at approximately $1.3 billion.
SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc.
Business Wire - Fri Feb 14, 12:06PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc ("MNK").
Downgrade Alert for Cadence Pharmaceuticals (CADX)
Comtex SmarTrend(R) - Fri Feb 14, 6:58AM CST
Cadence Pharmaceuticals (NASDAQ:CADX) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $14.04 on volume of 4.3 million shares, above average daily volume of 3.5 million. In the past 52 weeks, Cadence Pharmaceuticals share prices have been bracketed by a low of $4.45 and a high of $14.04 and closed yesterday at $14.04, 216% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 2.5% while the 200-day MA has risen 1.2%.
INVESTOR ALERT: LEVI & KORSINSKY, LLP Announces Investigation of CADENCE PHARMACEUTICALS INC. and Its Board of Directors in Connection with the Sale of the Company to Mallinckrodt plc -- CADX
Business Wire - Thu Feb 13, 4:33PM CST
Levi & Korsinsky is investigating the Board of Directors of Cadence Pharmaceuticals Inc. ("Cadence" or "the Company") (NasdaqGS:CADX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Mallinckrodt plc.
CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP is Investigating Cadence Pharmaceuticals, Inc. (CADX) in Relation to the Proposed Sale of the Company to Mallinckrodt plc
Business Wire - Thu Feb 13, 2:24PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc. ("Cadence" or the "Company") (NasdaqGS:CADX) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Mallinckrodt in a cash deal valued at approximately $1.3 billion. Under the terms of the proposed transaction, Cadence's stockholders will receive $14.00 for each share of Cadence common stock they own.
Everyone Wins in This Big Pharma Buyout
David Williamson, The Motley Fool - Motley Fool - Wed Feb 12, 7:30PM CST
Shares of Mallinckrodt were up 10% after the company announced that it's buying Cadence for $1.3 billion. Shares of Cadence performed even better, up about 25% on the buyout news. The catalyst for the acquisition is painkiller Ofirmev, which...
(0)
(0)